Aprea Therapeutics, Inc.
APRENasdaq
$0.71
↑ +2.8%Jul 17 close · end-of-day
Price
1Y↓ -57.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$10.4M
Enterprise Value
-$36.0M
P/E
—
P/S
—
P/B
0.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$12.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-28.7%
ROIC
—
Debt / Equity
—
Net Cash
$46.5M
Return 1Y
-57.5%
Company profile
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246, a small molecule p53 reactivator, which is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia (AML)
- CEO
- Oren Gilad
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Pennsylvania
- Website
- atrinpharma.com
Management & directors
- Gilad OrenPresident/CEO
- Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr
Roles derived from SEC Form 4 filings.
Earnings
APRE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.22↓ -66.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | — | -$37.4M | -$113.4M | -$15.5M | -$14.3M | -$13.2M |
| Net income | -$53.5M | -$37.1M | -$112.7M | -$14.3M | -$13.0M | -$12.6M |
| Diluted EPS | -$50.61 | -$34.88 | -$67.99 | -$3.95 | -$2.35 | -$1.93 |
| Operating cash flow | -$41.8M | -$37.7M | -$25.0M | -$12.2M | -$13.6M | -$12.9M |
| Free cash flow | -$41.8M | — | — | -$12.3M | -$13.6M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.8M | -$4.1M | -$3.2M | -$4.1M | -$3.4M | -$3.1M | -$2.6M | -$3.4M |
| Net income | -$3.5M | -$3.8M | -$2.9M | -$3.9M | -$3.2M | -$3.0M | -$2.5M | -$3.3M |
| Diluted EPS | -$0.58 | -$0.64 | -$0.46 | -$0.66 | -$0.53 | -$0.47 | -$0.27 | -$0.22 |
| Operating cash flow | -$3.6M | -$2.5M | -$3.5M | -$3.6M | -$3.1M | -$3.2M | -$3.0M | -$2.8M |
| Free cash flow | -$3.6M | -$2.5M | -$3.5M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-16 | Grissinger Michael | Award | 3,135 | $0.00 | $0.00 | filing |
| 2026-06-16 | Gruia Gabriela | Award | 3,135 | $0.00 | $0.00 | filing |
| 2026-06-16 | Peters Richard | Award | 3,135 | $0.00 | $0.00 | filing |
| 2026-06-16 | HENNEMAN JOHN B III | Award | 3,135 | $0.00 | $0.00 | filing |
| 2026-06-16 | BIZZARI JEAN-PIERRE | Award | 3,135 | $0.00 | $0.00 | filing |
| 2026-06-16 | Duey Marc | Award | 3,135 | $0.00 | $0.00 | filing |
| 2026-06-16 | Pamukcu Rifat | Award | 3,135 | $0.00 | $0.00 | filing |
| 2026-06-16 | Seizinger Bernd R. | Award | 3,135 | $0.00 | $0.00 | filing |
| 2026-03-12 | Gilad Oren· President/CEO | Award | 20,175 | $0.00 | $0.00 | filing |
| 2026-03-12 | Hamill John P.· SrVP/CFO/Prin Fin & Acct Ofcr | Award | 10,095 | $0.00 | $0.00 | filing |
| 2026-01-30 | Gilad Oren· President/CEO | Buy | 28,100 | $0.89 | $25,009.00 | filing |
| 2026-01-30 | Hamill John P.· SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 5,700 | $0.89 | $5,073.00 | filing |
| 2025-12-10 | Duey Marc | Buy | 21,459 | $1.17 | $24,999.74 | filing |
| 2025-12-10 | Hamill John P.· SrVP/CFO/Prin Fin & Acct Ofcr | Buy | 5,000 | $1.17 | $5,825.00 | filing |
Latest 14 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.